First UK patients to get Merck's Keytruda after landmark early access decision
This article was originally published in Scrip
Executive Summary
Merck says its new drug for advanced melanoma, pembrolizumab, is expected to be made available in the UK very soon, after it became the first product to gain a scientific opinion under the UK's Early Access to Medicines Scheme (EAMS).